Xencor, Inc.

Is Xencor, Inc. technically bullish or bearish?

As of October 31, 2025, Xencor, Inc. shows a mildly bullish technical trend despite significant underperformance compared to the S&P 500, with mixed signals from various indicators.

As of 31 October 2025, the technical trend for Xencor, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, indicating positive momentum. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish on the weekly but bearish on the monthly, adding some mixed signals. Overall, the Dow Theory indicates a mildly bullish stance on the weekly timeframe.<BR><BR>In terms of performance, Xencor has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -40.38% versus the S&P 500's 16.30%, and a 1-year return of -35.56% compared to the S&P 500's 19.89%. This underperformance highlights the challenges the stock faces despite its current mildly bullish technical stance.

Is Xencor, Inc. overvalued or undervalued?

As of February 23, 2023, Xencor, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics, including a Price to Book Value of 1.07, an EV to Sales ratio of 2.95, a troubling ROCE of -50.84%, and a year-to-date stock return of -56.35% compared to the S&P 500's gain of 12.22%.

As of 23 February 2023, Xencor, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.07, an EV to Sales ratio of 2.95, and a troubling ROCE of -50.84%. In comparison to peers, Xencor's EV to EBITDA ratio of -2.42 is significantly worse than Vir Biotechnology, Inc. at -0.0645 and Maravai Lifesciences Holdings, Inc. at -15.5085, indicating a challenging position within the industry.<BR><BR>Additionally, Xencor's stock has underperformed relative to the S&P 500, with a year-to-date return of -56.35% compared to the index's gain of 12.22%. This stark contrast reinforces the notion that Xencor is currently overvalued in light of its financial performance and relative standing among its peers.

How big is Xencor, Inc.?

As of Jun 18, Xencor, Inc. has a market capitalization of 591.43 million and reported net sales of 127.23 million with a net profit of -211.05 million over the latest four quarters. Shareholder's funds are at 677.61 million and total assets at 951.95 million as of Dec 24.

As of Jun 18, Xencor, Inc. has a market capitalization of 591.43 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 127.23 million, while the sum of Net Profit for the same period is -211.05 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 677.61 million and Total Assets at 951.95 million.

What does Xencor, Inc. do?

Xencor, Inc. is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for severe diseases. As of March 2025, it reported net sales of $33 million and a net loss of $49 million, with a market cap of $591.43 million.

Overview:<BR>Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 33 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -49 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 591.43 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.49 <BR>Return on Equity: -32.74% <BR>Price to Book: 0.92 <BR><BR>Contact Details:<BR>Address: 111 W Lemon Ave, MONROVIA CA : 91016-2809 <BR>Tel: 1 626 3055900 <BR>Fax: 1 626 3050350 <BR>Website: http://www.xencor.com/

Should I buy, sell or hold Xencor, Inc.?

Who are in the management team of Xencor, Inc.?

As of March 2022, Xencor, Inc.'s management team includes Dr. Bassil Dahiyat as President and CEO, with Dr. A. Bruce Montgomery as Lead Independent Director and other Independent Directors: Dr. Ellen Feigal, Dr. Kevin Gorman, Mr. Kurt Gustafson, and Mr. Yujiro Hata.

As of March 2022, the management team of Xencor, Inc. includes Dr. Bassil Dahiyat, who serves as the President, Chief Executive Officer, Founder, and Director. Additionally, the Board of Directors features Dr. A. Bruce Montgomery as the Lead Independent Director, along with Dr. Ellen Feigal, Dr. Kevin Gorman, Mr. Kurt Gustafson, and Mr. Yujiro Hata, all of whom are Independent Directors.